ERBB2 and breast cancer: The study enrolled 19 patients and was planned to evaluate the ORR of TVB-2640 in combination with paclitaxel and trastuzumab in patients with paclitaxel- and trastuzumab-resistant advanced HER2-positive breast cancer, and changes in FASN, phosphorylated (p)AKT, and pS6 expression in the tumor tissues after the first cycle of the treatment.